Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1

Journal of Diabetes

Volumn 7, Issue 1, 2015, Pages 114-124

  Serban, Andreea Iren ^a   Stanca, Loredana ^a   Geicu, Ovidiu Ionut ^a,b   Munteanu, Maria Cristina ^b   Costache, Marieta ^b   Dinischiotu, Anca ^b  

^a UNIVERSITY OF AGRONOMIC SCIENCES AND VETERINARY MEDICINE OF BUCHAREST   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Advanced glycation end products; Aminoguanidine; Matrix hypertrophy; Matrix metalloproteinase; Transforming growth factor 1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BOVINE SERUM ALBUMIN; COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN RECEPTOR; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; BOVINE; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CATTLE; COLLAGEN TYPE IV; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HEK293 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84920053904     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12154     Document Type: Article

References (43)

1. Brizzi MF, Dentelli P, Rosso A etal. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: A possible role in the development and progression of diabetic nephropathy. FASEB J. 2004; 18: 1249-1251.
2. Ruan X, Guan Y. Metabolic syndrome and chronic kidney disease. J Diabetes. 2009; 1: 236-245.
3. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol. 2003; 162: 1937-1949.
4. Li JH, Wang W, Huang XR etal. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol. 2004; 164: 1389-1397.
5. Menini S, Iacobini C, Ricci C etal. Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation. Diabetologia. 2007; 50: 1997-2007.
6. Wendt T, Tanji N, Guo J etal. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003; 14: 1383-1395.
7. Lenz W, Herten M, Gerzer R, Drummer C. Regulation of natriuretic peptide (urodilatin) release in a human kidney cell line. Kidney Int. 1999; 55: 91-99.
8. Biemel KM, Conrad J, Lederer MO. Unexpected carbonyl mobility in aminoketoses: The key to major Maillard crosslinks. Angew Chem Int Ed. 2002; 41: 801-804.
9. Hodge JE. The Amadori rearrangement. Adv Carbohydr Chem. 1955; 10: 169-205.
10. Sell DR, Biemel KM, Reihl O, Lederer MO, Strauch CM, Monnier VM. Glucosepane is a major protein cross-link of the senescent human extracellular matrix. Relationship with diabetes. J Biol Chem. 2005; 280: 12-310.
11. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009; 52: 2251-2263.
12. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol. 2003; 23: 532-543.
13. Shimizu F, Sano Y, Haruki H, Kanda T. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia. 2011; 54: 1517-1526.
14. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232: 1629-1632.
15. Serban AI, Costache M, Dinischiotu A. AGEs and glucose levels modulate type I and III procollagen mRNA synthesis in dermal fibroblasts cells culture. Exp Diabetes Res. 2008; 2008: 473603. doi: 10.1155/2008/473603.
16. Serban AI, Costache M, Dinischiotu A. Controversial behavior of aminoguanidine in the presence of either reducing sugars or soluble glycated bovine serum albumin. Carbohydr Res. 2011; 346: 2872-2880.
17. Komsa-Penkova R, Spirova R, Bechev B. Modification of Lowry's method for collagen concentration measurement. J Biochem Biophys Methods. 1996; 32: 33-43.
18. Romero-Calvo I, Ocón B, Martínez-Moya P etal. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal Biochem. 2010; 401: 318-320.
19. Ruangpanit N, Chan D, Holmbeck K etal. Gelatinase A (MMP-2) activation by skin fibroblasts: Dependence on MT1-MMP expression and fibrillar collagen form. Matrix Biol. 2001; 20: 193-203.
20. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: 2002-2007.
21. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J Lab Clin Med. 2001; 138: 59-68.
22. Du X, Shimizu A, Masuda Y etal. Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy. Lab Invest. 2012; 92: 1149-1160.
23. Zheng G, Lyons JG, Tan TK etal. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor- β1 in renal tubular epithelial cells. Am J Pathol. 2009; 175: 580-591.
24. Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Exp Pathol. 2011; 92: 143-150.
25. Cadigan KM, Nusse R. Wnt signaling: A common theme in animal development. Genes Dev. 1997; 11: 3286-3305.
26. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: Role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24: 7443-7454.
27. Wendt T, Tanji N, Guo J etal. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003; 162: 1123-1137.
28. Bierhaus A, Humpert PM, Morcos M etal. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005; 83: 876-886.
29. Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med. 2009; 87: 235-247.
30. Tobar N, Villar V, Santibanez JF. ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion. Mol Cell Biochem. 2010; 340: 195-202.
31. Soro-Paavonen A, Watson AMD, Li J etal. Receptor for advanced glycation end products (RAGE) eficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 2008; 57: 2461-2469.
32. Perrone L, Peluso G, Melone MAB. RAGE recycles at the plasma membrane in S100B secretory vesicles and promotes Schwann cells morphological changes. J Cell Physiol. 2008; 217: 60-71.
33. Spangler JB, Neil JR, Abramovitch S etal. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A. 2010; 107: 13252-13257.
34. Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-β as the major mediator. J Am Soc Nephrol. 2004; 15: S55-S57.
35. Bucala R, Makita Z, Vega G etal. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994; 91: 9441-9445.
36. Hammes HP, Strödter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia. 1995; 38: 656-660.
37. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts (AGEs). Arch Biochem Biophys. 2003; 419: 31-40.
38. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, Witztum JL. Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vasc Biol. 1995; 15: 367-376.
39. Skamarauskas JS, McKay AG, Hunt JV. Aminoguanidine and its pro-oxidant effects on an experimental model of protein glycation. Free Radic Biol Med. 1996; 21: 801-812.
40. Shi Fang Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) & its ligands - cast into leading roles in diabetes & the inflammatory response. J Mol Med. 2009; 87: 235-247.
41. Zhang Q, Ames JM, Smith RD, Baynes JW, Metz TO. A Perspective on the Maillard Reaction and the analysis of protein glycation by Mass Spectrometry: Probing the pathogenesis of chronic disease. J Proteome Res. 2009; 8: 754-769.
42. Feng L, Zhu MM, Zhang MH, Jia XB. N-Epsilon-(carboxymethyl)lysine is unable to induce endothelial dysfunction but is able to attenuate AGEs-induced endothelium damage in human umbilical vein endothelial cells. Pharmazie. 2013; 68: 251-256.
43. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes. 1998; 47: 1114-1120.